The UK clinical trials landscape has experienced a significant boost in advanced therapy research, with a notable surge in Phase I trials. Data released by the Cell and Gene Therapy Catapult indicates a 70% increase in Phase I advanced therapy medicinal product (ATMP) studies across the UK in 2024. This growth underscores the UK's strengthening position as a hub for innovative medical research and development.
The Cell and Gene Therapy Catapult reported a total of 187 ATMP trials in the UK throughout 2024, marking a 7% increase compared to the previous year. Specifically, the number of Phase I trials rose from 24 to 41 during the same period. The research also highlights that the UK accounts for 9.5% of all global trials and nearly 50% of all European trials in 2024.
Oncology Dominates ATMP Research
The data reveals that oncology remains the dominant sector in ATMP research within the UK, accounting for 38% of all trials. Metabolic indications follow, representing 13% of UK trials, while hematological indications account for 10%. A significant portion, 81%, of these studies involve some form of genetically modified therapy.
ATMPs encompass gene therapy medicines, somatic-cell therapy medicines, and tissue-engineered medicines, representing a cutting-edge approach to treating various diseases.
Industry Perspective
Matthew Durdy, chief executive of Cell and Gene Therapy Catapult, emphasized the importance of these trials, stating, "Advanced therapy clinical trials are important in two regards. They provide a clear indication of the attractiveness of the UK for advanced therapy product development and they create the skills, capabilities and environment that mean that patients can access these life-changing drugs more quickly and easily. This data shows the UK’s continued strength on both counts."
UK's Clinical Trial Ranking
This positive trend follows earlier findings by the Association of the British Pharmaceutical Industry (ABPI), which indicated that the UK has regained its status as a key center for clinical trials. After falling from fourth to tenth place globally between 2017 and 2021, the UK has now climbed back to eighth position, although it still lags behind some of its European counterparts.
The increase in ATMP trials and the UK's improved ranking reflect ongoing efforts to enhance the country's clinical research environment and attract investment in innovative therapies.
